Seven public companies rolled out new products and approvals in the past two weeks, from Apple's new home devices to three FDA drug approvals. Each launch below has a quick summary, a source, and a notes box. Your notes save automatically in this browser. Updated October 13, 2026.
This week's product releases
Apple (NASDAQ: AAPL): Apple HomeView and new Apple TV 4K
Apple introduced HomeView, a 7-inch smart-home display, alongside a new Apple TV 4K, both built around its new Siri AI assistant. HomeView is $299 in the U.S., with pre-orders open now and both devices arriving November 13. It's Apple's push to bring its AI into the living room, a new way to grow hardware and services beyond the iPhone.
Alphabet (NASDAQ: GOOGL): Gemini 4 Argon AI model
Google made its newest frontier AI model, Gemini 4 Argon, available to developers, businesses, and paying Gemini subscribers. Developers pay an introductory $2 per million input tokens and $10 per million output tokens through November 30, then $4 and $20. Paid AI access is a growing revenue line, so adoption of Argon is worth watching in Alphabet's cloud results.
Meta Platforms (NASDAQ: META): Muse Wonder AI models
Meta released Muse Wonder and Muse Wonder Full, which it calls its most capable AI models, for personal and work tasks. They're available now through the Meta Model API and Muse Code, and were trained at Meta's gigawatt-scale Prometheus data center. It's an early look at the payoff from Meta's heavy AI spending.
NVIDIA (NASDAQ: NVDA): RTX Spark laptops
NVIDIA's RTX Spark chip brings its graphics and AI hardware to slim Windows laptops from partner PC makers. The chip pairs a Blackwell RTX GPU with up to 6,144 CUDA cores and a Grace CPU with up to 20 cores. It's a step into everyday laptops, a big market beyond the data center.
Eli Lilly (NYSE: LLY): Jaypirca approved for first-line CLL/SLL
The FDA approved Lilly's Jaypirca for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. Moving into first-line treatment opens the drug to patients at the start of their care. That's a much larger group than patients whose earlier treatments stopped working.
Novartis (NYSE: NVS): Rhapsido approved for symptomatic dermographism
The FDA approved Novartis's Rhapsido pill as the first treatment for symptomatic dermographism, hives triggered by skin friction, in adults not helped by antihistamines. Rhapsido is now the only drug approved for the two most common forms of chronic hives. A second approved use helps a newer drug build sales faster.
Pfizer (NYSE: PFE): Tukysa approved for HER2-positive breast cancer maintenance
The FDA approved Pfizer's Tukysa, with trastuzumab and pertuzumab, as maintenance treatment for adults with advanced HER2-positive breast cancer after initial treatment. Maintenance use can mean patients stay on a drug longer. That can add steady sales for one of Pfizer's cancer medicines from its Seagen deal.
Notes stay on this device only. Nothing is sent to us.
How product launches move stocks
Expectations matter most
Big launches are often expected weeks ahead, so the stock may already reflect the news. The move on launch day depends on whether price, features, or timing beat or miss what investors expected.
Sales show up later
A product announced today usually reaches earnings reports a quarter or two later. Pre-orders, reviews, and early demand are the first signs to watch.
Drug approvals open new markets
An FDA approval lets a company sell a drug for a new use. A first-line or broader approval can widen the patient group, which is why expanded approvals often matter as much as brand-new drugs.
Big companies, smaller moves
For giants like Apple or Alphabet, one product is a small piece of total revenue. For smaller companies, a single launch or approval can move the stock much more.
Get big launches as they happen
Free special alerts by text on new product releases, investment opportunities, and big market moves.
Get free text alerts →This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice. Product details and timing can change. Do your own research or talk with a licensed professional before making investment decisions.